{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:52:56Z","timestamp":1786135976262,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clgc.2026.102609","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:49:26Z","timestamp":1783666166000},"page":"102609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9124-354X","authenticated-orcid":false,"given":"Ben","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-5182","authenticated-orcid":false,"given":"Madeline","family":"Richey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Hankinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-5743","authenticated-orcid":false,"given":"Smriti","family":"Karwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Sharpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Braunlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0257-8696","authenticated-orcid":false,"given":"Christopher","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2026.102609_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: a cancer journal for clinicians."},{"key":"10.1016\/j.clgc.2026.102609_bib0002","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/GO.20.00511","article-title":"Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)","volume":"7","author":"Maluf","year":"2021","journal-title":"JCO global oncology."},{"issue":"7","key":"10.1016\/j.clgc.2026.102609_bib0003","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","article-title":"Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review","volume":"23","author":"Patell","year":"2023","journal-title":"Expert review of anticancer therapy."},{"issue":"12","key":"10.1016\/j.clgc.2026.102609_bib0004","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med."},{"issue":"10459","key":"10.1016\/j.clgc.2026.102609_bib0005","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"(177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.clgc.2026.102609_bib0006","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research."},{"key":"10.1016\/j.clgc.2026.102609_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.63","article-title":"Patient Characteristics and Overall Survival with Lutetium (Lu177) Vipivotide Tetraxetan (177Lu-PSMA-617): A Real-World Analysis of Early Adopters","volume":"43","author":"George","year":"2025","journal-title":"Journal of Clinical Oncology."},{"issue":"3","key":"10.1016\/j.clgc.2026.102609_bib0008","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw."},{"issue":"6","key":"10.1016\/j.clgc.2026.102609_bib0009","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and Validation of a High-Quality Composite Real-World Mortality Endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health services research."},{"issue":"6","key":"10.1016\/j.clgc.2026.102609_bib0010","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real-world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health services research."},{"issue":"8","key":"10.1016\/j.clgc.2026.102609_bib0011","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/pros.24880","article-title":"Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience","volume":"85","author":"Losee","year":"2025","journal-title":"Prostate."},{"key":"10.1016\/j.clgc.2026.102609_bib0012","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.77","article-title":"Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Kostos","year":"2023","journal-title":"Journal of Clinical Oncology."},{"key":"10.1016\/j.clgc.2026.102609_bib0013","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.2147\/OTT.S103532","article-title":"Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations","volume":"10","author":"Patel","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"3","key":"10.1016\/j.clgc.2026.102609_bib0014","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/j.clgc.2019.03.008","article-title":"Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis","volume":"17","author":"Leal","year":"2019","journal-title":"Clinical genitourinary cancer"},{"key":"10.1016\/j.clgc.2026.102609_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.105","article-title":"A Randomized Phase II study of 177Lu-PSMA-617 versus Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and PSMA-positive Disease: Canadian Cancer Trials Group (CCTG) Study PR.21","volume":"36","author":"Chi","year":"2025","journal-title":"Annals of Oncology."},{"issue":"26","key":"10.1016\/j.clgc.2026.102609_bib0016","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.clgc.2026.102609_bib0017","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2021.06.021","article-title":"Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study","volume":"80","author":"Sternberg","year":"2021","journal-title":"Eur Urol."},{"issue":"4","key":"10.1016\/j.clgc.2026.102609_bib0018","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bju.15542","article-title":"Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer","volume":"129","author":"Kreis","year":"2022","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.clgc.2026.102609_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102386","article-title":"Real-World Treatment Patterns and Survival in People With Metastatic Castration-Resistant Prostate Cancer Following Metastatic Hormone-Sensitive Disease Between 2020 and 2023 in the United States","volume":"23","author":"Raval","year":"2025","journal-title":"Clinical genitourinary cancer."},{"issue":"12","key":"10.1016\/j.clgc.2026.102609_bib0020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41416-019-0611-6","article-title":"Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort","volume":"121","author":"Rouyer","year":"2019","journal-title":"Br J Cancer."},{"key":"10.1016\/j.clgc.2026.102609_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1108937","article-title":"Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland","volume":"13","author":"Sigorski","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.clgc.2026.102609_bib0022","article-title":"A multi-center retrospective cohort study of patients with mCRPC who received lutetium Lu177 vipivotide tetraxetan","volume":"42","author":"Desai","year":"2025","journal-title":"Journal of Clinical Oncology."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:59:31Z","timestamp":1786132771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1558767326001096"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102609","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102609"}}